Literature DB >> 18842409

A diaminocyclohexyl analog of SNS-032 with improved permeability and bioavailability properties.

Ingrid C Choong1, Iana Serafimova, Junfa Fan, David Stockett, Erica Chan, Sravanthi Cheeti, Yafan Lu, Bruce Fahr, Phuongly Pham, Michelle R Arkin, Duncan H Walker, Ute Hoch.   

Abstract

The identification of a selective CDK2, 7, 9 inhibitor 4 with improved permeability is described. Compound 4 exhibits comparable CDK selectivity profile to SNS-032, but shows improved permeability and higher bioavailability in mice.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18842409     DOI： 10.1016/j.bmcl.2008.09.073

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  4 in total

Review 1.  Cell cycle kinases as therapeutic targets for cancer.

Authors:  Silvia Lapenna; Antonio Giordano
Journal:  Nat Rev Drug Discov       Date:  2009-07       Impact factor: 84.694

2.  Identification of inhibitors of the Leishmania cdc2-related protein kinase CRK3.

Authors:  Laura A T Cleghorn; Andrew Woodland; Iain T Collie; Leah S Torrie; Neil Norcross; Torsten Luksch; Chido Mpamhanga; Roderick G Walker; Jeremy C Mottram; Ruth Brenk; Julie A Frearson; Ian H Gilbert; Paul G Wyatt
Journal:  ChemMedChem       Date:  2011-09-13       Impact factor: 3.466

3.  Development of a cyclin-dependent kinase inhibitor devoid of ABC transporter-dependent drug resistance.

Authors:  M Kaliszczak; H Patel; S H B Kroll; L Carroll; G Smith; S Delaney; D A Heathcote; A Bondke; M J Fuchter; R C Coombes; A G M Barrett; S Ali; E O Aboagye
Journal:  Br J Cancer       Date:  2013-09-26       Impact factor: 7.640

4.  Virtual Screening Using Pharmacophore Models Retrieved from Molecular Dynamic Simulations.

Authors:  Pavel Polishchuk; Alina Kutlushina; Dayana Bashirova; Olena Mokshyna; Timur Madzhidov
Journal:  Int J Mol Sci       Date:  2019-11-20       Impact factor: 5.923
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.